Abstract | BACKGROUND: METHODS: RESULTS:
Induction chemotherapy may be beneficial for node-positive esophageal cancer, although the consensus has not yet been established. A regimen of induction chemotherapy should have a high response rate and cisplatin/5-FU may be underpowered as an induction setting. DCF can be a candidate for the regimen of induction chemotherapy for esophageal cancer, although severe adverse events have been reported. Several modified regimens to reduce the toxicity have been reported. The response rate of our series was 61% and a significant decrease in standardized uptake values was observed after the induction chemotherapy. Although high-grade neutropenia was still observed with this regimen, neither treatment-related death nor delay in the following treatment was observed. CONCLUSIONS:
|
Authors | Masayuki Watanabe, Yohei Nagai, Kuichi Kinoshita, Seiya Saito, Junji Kurashige, Ryuichi Karashima, Kotaro Hirashima, Nobutaka Sato, Yu Imamura, Yukiharu Hiyoshi, Yoshifumi Baba, Shiro Iwagami, Yuji Miyamoto, Masaaki Iwatsuki, Naoko Hayashi, Hideo Baba |
Journal | Digestion
(Digestion)
Vol. 83
Issue 3
Pg. 146-52
( 2011)
ISSN: 1421-9867 [Electronic] Switzerland |
PMID | 21266808
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2011 S. Karger AG, Basel. |
Chemical References |
- Taxoids
- Docetaxel
- Cisplatin
- Fluorouracil
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Cisplatin
(administration & dosage, adverse effects)
- Docetaxel
- Esophageal Neoplasms
(drug therapy, pathology)
- Fluorouracil
(administration & dosage, adverse effects)
- Humans
- Lymphatic Metastasis
- Neoadjuvant Therapy
- Taxoids
(administration & dosage, adverse effects)
|